心脉医疗 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	1.2B	1.2B	897.0M	685.0M	470.0M
Revenue Growth %	1.6%	32.3%	30.9%	45.7%	--
Total Revenue	1.2B	1.2B	897.0M	685.0M	470.0M
Cost Of Revenue	326.0M	280.0M	223.0M	150.0M	98.3M
+Gross Profit	880.0M	907.0M	674.0M	535.0M	371.7M
Gross Margin %	73.0%	76.4%	75.1%	78.1%	79.1%
Total Operating Cost	671.0M	649.0M	512.0M	355.0M	249.0M
Selling Expenses	157.0M	130.0M	104.0M	75.7M	59.5M
Admin Expenses	93.4M	55.0M	46.0M	29.2M	19.8M
Rd Expenses	93.8M	173.0M	138.0M	102.0M	73.0M
Finance Expenses	-16.6M	-8.4M	-10.9M	-11.4M	-7.7M
+Operating Income	661.0M	574.0M	415.0M	363.0M	250.0M
Operating Margin %	54.8%	48.4%	46.3%	53.0%	53.2%
Non Operating Income	59,500	334,600	346,300	527,500	38,500
Non Operating Expenses	9.0M	1.9M	1.7M	1.6M	420,000
Investment Income	87.4M	9.1M	4.1M	15.0M	13.9M
Asset Disposal Income	25,500	--	--	--	-40,900
Asset Impairment Loss	4.7M	6.4M	2.2M	2.6M	2.1M
Other Income	38.8M	26.5M	26.9M	18.4M	14.4M
Income Before Tax	652.0M	572.0M	414.0M	362.0M	250.0M
Income Tax	159.0M	85.0M	61.8M	48.1M	34.9M
+Net Income	493.0M	487.0M	352.0M	314.0M	215.0M
Net Margin %	40.9%	41.0%	39.2%	45.8%	45.7%
Net Income Attributable	502.0M	492.0M	357.0M	316.0M	215.0M
Minority Interest	-9.4M	-5.2M	-4.8M	-2.3M	--
Eps Basic	4.07	6.81	4.96	4.39	2.98
Eps Diluted	4.07	6.81	4.96	4.39	2.98

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	2.2B	3.0B	977.0M	1.2B	1.1B
Accounts Receivable	210.0M	148.0M	124.0M	73.2M	48.8M
Notes And Accounts Receivable	210.0M	148.0M	124.0M	73.2M	48.8M
Prepayments	38.2M	33.0M	20.6M	33.9M	14.5M
Inventory	266.0M	211.0M	156.0M	107.0M	82.1M
Total Current Assets	2.7B	3.4B	1.3B	1.5B	1.2B
Long Term Equity Investment	--	122.0M	126.0M	--	--
Fixed Assets	--	97.1M	86.7M	70.0M	51.2M
Fixed Assets Total	101.0M	97.1M	86.7M	70.0M	51.2M
Construction In Progress	--	206.0M	101.0M	2.3M	2.4M
Construction In Progress Total	288.0M	206.0M	101.0M	2.3M	2.4M
Intangible Assets	440.0M	208.0M	219.0M	76.1M	60.6M
Long Term Deferred Expenses	25.4M	35.3M	46.3M	38.6M	8.8M
Total Non Current Assets	1.6B	881.0M	701.0M	295.0M	179.0M
Total Assets	4.3B	4.2B	2.0B	1.8B	1.4B
Short Term Borrowings	14.0M	--	--	--	--
Accounts Payable	41.3M	40.4M	42.1M	24.8M	17.8M
Advance Receipts	--	--	--	--	--
Contract Liabilities	4.6M	1.9M	2.5M	2.2M	2.7M
Total Current Liabilities	339.0M	313.0M	187.0M	162.0M	115.0M
Total Non Current Liabilities	130.0M	69.9M	65.7M	69.4M	27.4M
Total Liabilities	469.0M	383.0M	252.0M	231.0M	142.0M
Paid In Capital	123.0M	82.7M	72.0M	72.0M	72.0M
Capital Reserve	2.7B	2.6B	835.0M	818.0M	809.0M
Surplus Reserve	61.6M	41.4M	36.0M	36.0M	36.0M
Retained Earnings	1.1B	1.1B	774.0M	568.0M	317.0M
Minority Equity	30.6M	19.8M	24.0M	27.8M	--
Equity Attributable	3.8B	3.8B	1.7B	1.5B	1.2B
Total Equity	3.8B	3.9B	1.7B	1.5B	1.2B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	1.2B	1.3B	951.0M	751.0M	517.0M
Tax Refunds Received	--	--	--	458,000	--
Total Operating Cash Inflow	1.3B	1.4B	994.0M	780.0M	543.0M
Cash Paid For Goods	268.0M	265.0M	180.0M	162.0M	105.0M
Cash Paid To Employees	253.0M	232.0M	190.0M	138.0M	92.4M
Taxes Paid	284.0M	174.0M	141.0M	120.0M	80.7M
Total Operating Cash Outflow	942.0M	800.0M	661.0M	480.0M	325.0M
Operating Cash Flow	374.0M	558.0M	334.0M	300.0M	217.0M
Total Investing Cash Inflow	4.7B	1.6B	2.6B	1.4B	2.4B
Total Investing Cash Outflow	5.4B	1.8B	3.0B	1.5B	2.4B
Investing Cash Flow	-733.0M	-177.0M	-440.0M	-74.6M	-8.7M
Cash From Borrowings	14.0M	--	2.1M	--	--
Dividends And Interest Paid	450.0M	166.0M	151.0M	64.8M	46.8M
Debt Repayments	--	2.1M	0.00	--	--
Total Financing Cash Inflow	49.0M	1.8B	2.1M	35.0M	0.00
Total Financing Cash Outflow	584.0M	180.0M	162.0M	74.8M	46.8M
Financing Cash Flow	-535.0M	1.6B	-160.0M	-39.8M	-46.8M
Net Change In Cash	-894.0M	2.0B	-266.0M	186.0M	162.0M
Ending Cash Balance	2.1B	3.0B	971.0M	1.2B	1.1B
Capex	213.0M	190.0M	294.0M	89.6M	26.2M